Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

Imhof, Anna; Brunner, Philippe; Marincek, Nicolas; Briel, Matthias; Schindler, Christian; Rasch, Helmut; Mäcke, Helmut R; Rochlitz, Christoph; Müller-Brand, Jan; Walter, Martin A (2011). Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology, 29(17), pp. 2416-23. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.33.7873

Full text not available from this repository. (Request a copy)

To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Walter, Martin Alexander

ISSN:

0732-183X

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:19

Last Modified:

06 Dec 2013 13:26

Publisher DOI:

10.1200/JCO.2010.33.7873

PubMed ID:

21555692

Web of Science ID:

000291385200035

URI:

https://boris.unibe.ch/id/eprint/6158 (FactScience: 211060)

Actions (login required)

Edit item Edit item
Provide Feedback